A carregar...
Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis
BACKGROUND: The anti–human epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab improves outcomes in patients with node-positive HER2+ early breast cancer. Given trastuzumab’s high cost, we aimed to estimate its cost-effectiveness by heterogeneity in age and estrogen receptor (E...
Na minha lista:
| Publicado no: | PLoS Med |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4978494/ https://ncbi.nlm.nih.gov/pubmed/27504960 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.1002067 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|